Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer (ARC-10)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04736173

Recruitment Status : Active, not recruiting

First Posted : February 3, 2021

Last Update Posted : March 15, 2024

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

Gilead Sciences

Information provided by (Responsible Party):

Arcus Biosciences, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	August 31, 2024
Estimated Study Completion Date :	July 1, 2027

To Top